No conflict of interest was declared.
Identification of responders and reactive domains to rivastigmine in Alzheimer's disease†
Article first published online: 16 NOV 2006
Copyright © 2006 John Wiley & Sons, Ltd.
Pharmacoepidemiology and Drug Safety
Volume 16, Issue 5, pages 545–551, May 2007
How to Cite
Frankfort, S. V., Appels, B. A., de Boer, A., Tulner, L. R., van Campen, J. P. C. M., Koks, C. H. W., Beijnen, J. H. and Schmand, B. A. (2007), Identification of responders and reactive domains to rivastigmine in Alzheimer's disease. Pharmacoepidem. Drug Safe., 16: 545–551. doi: 10.1002/pds.1345
- Issue published online: 1 MAY 2007
- Article first published online: 16 NOV 2006
- Manuscript Accepted: 3 OCT 2006
- Manuscript Revised: 20 SEP 2006
- Manuscript Received: 23 MAY 2006
- Alzheimer's disease;
- cognitive domains;
Presently, it is unclear which patients suffering from Alzheimer's Disease (AD) respond to rivastigmine and if rivastigmine acts on specific cognitive domains. The aims of this study are thus to investigate treatment effects of rivastigmine on specific cognitive domains and to find possible responsive subpopulations to rivastigmine cognitive effects.
Mini Mental State Examination (MMSE) and Cambridge Cognitive Examination (CAMCOG) were administered at baseline and after 6 months in 83 rivastigmine users and 96 historical controls, representing natural decline. Treatment effects on different subsections of the CAMCOG and in different subpopulations were investigated by linear regression analyses.
Rivastigmine showed effectiveness on total CAMCOG (p < 0.001), CAMCOG non-memory subsection (p < 0.001) and subscales of language (p = 0.002), attention/calculation (p = 0.043), abstract thinking (p < 0.001) and perception (p = 0.031). In patients with baseline MMSE ≤19 rivastigmine showed significant and favourable effects compared to historical controls on total CAMCOG (p < 0.001) and both non-memory (p < 0.001) and memory subsections (p = 0.002).
Rivastigmine showed primarily effectiveness on the non-memory section of the CAMCOG and patients with a baseline MMSE ≤ 19 appeared to show greater responses to rivastigmine compared to patients with baseline MMSE ≥ 20. Copyright © 2006 John Wiley & Sons, Ltd.